Zoetis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Zoetis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ZTS

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. 

CEO
Kristin C. Peck
CEOKristin C. Peck
Employees
13,800
Employees13,800
Headquarters
Parsippany, New Jersey
HeadquartersParsippany, New Jersey
Founded
1952
Founded1952
Employees
13,800
Employees13,800

ZTS Key Statistics

Market cap
54.92B
Market cap54.92B
Price-Earnings ratio
21.11
Price-Earnings ratio21.11
Dividend yield
1.60%
Dividend yield1.60%
Average volume
4.71M
Average volume4.71M
High today
$125.90
High today$125.90
Low today
$123.47
Low today$123.47
Open price
$125.90
Open price$125.90
Volume
7.05M
Volume7.05M
52 Week high
$177.40
52 Week high$177.40
52 Week low
$115.25
52 Week low$115.25

Stock Snapshot

As of today, Zoetis(ZTS) shares are valued at $124.60. The company's market cap stands at 54.92B, with a P/E ratio of 21.11 and a dividend yield of 1.6%.

During the trading session on 2026-01-17, Zoetis(ZTS) shares reached a daily high of $125.90 and a low of $123.47. At a current price of $124.60, the stock is +0.9% higher than the low and still -1.0% under the high.

Trading volume for Zoetis(ZTS) stock has reached 7.05M, versus its average volume of 4.71M.

Over the past 52 weeks, Zoetis(ZTS) stock has traded between a high of $177.40 and a low of $115.25.

Over the past 52 weeks, Zoetis(ZTS) stock has traded between a high of $177.40 and a low of $115.25.

ZTS News

Simply Wall St 11h
A Look At Zoetis Valuation As Softer Sales Projections Stir Debate Before Q4 2025 Earnings

Zoetis (ZTS) heads into its upcoming Q4 2025 earnings release with investor attention fixed on softer sales projections for certain pet and livestock medicines...

A Look At Zoetis Valuation As Softer Sales Projections Stir Debate Before Q4 2025 Earnings
Simply Wall St 2d
Should Fundsmith’s Support and Librela Safety Reassessment Require Action From Zoetis Investors?

In 2025, Fundsmith Equity Fund began building a position in Zoetis Inc., describing it as a leading veterinary pharmaceutical company with limited generic compe...

Should Fundsmith’s Support and Librela Safety Reassessment Require Action From Zoetis Investors?

Analyst ratings

71%

of 21 ratings
Buy
71.4%
Hold
28.6%
Sell
0%

People also own

Based on the portfolios of people who own ZTS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .